A retrospective study reported an 87.5% complete remission rate with the CACAG-VEN regimen in newly diagnosed ELN 2022 adverse-risk acute myeloid leukemia. The findings add to the growing interest in epigenetic and venetoclax-adjacent strategies designed to improve depth of response in high-risk biology. While retrospective response rates require cautious interpretation, the data provide a concrete signal for further prospective evaluation and trial expansion aimed at sustaining remissions and improving survival in this subgroup.